A CAR-T therapy invented at Seattle Children’s was never approved for kids. Now the hospital is launching its own pediatric CAR-T startup
In 2021, the FDA approved Bristol Myers Squibb’s Breyanzi for some adult lymphoma patients, making it the third CAR-T therapy to become commercially available.
The treatment was invented at Seattle Children’s Hospital, and the first clinical study was in pediatric patients. Mike Jensen, chief therapeutics officer at Seattle Children’s and the physician-scientist behind Breyanzi, hoped that Bristol Myers would seek approval for children next.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.